1-Year Results Reported for Jenscare JensClip

June 9, 2025—Jenscare Scientific Co., Ltd. recently announced that 1-year outcomes from a study of the JensClip transcatheter mitral valve replacement (TMVR) system were presented by Professor Xiangbin Pan, MD, at EuroPCR 2025.

According to the company, the prospective, multicenter, single-arm clinical trial evaluated the safety and efficacy of the JensClip TMVR system for the treatment of patients with symptomatic degenerative mitral regurgitation (DMR) at high surgical risk.

Prof. Pan concluded that JensClip is an innovative device intended for severe DMR that provides easy and reliable operation and that the 1-year clinical outcomes demonstrated procedural safety and durable MR reduction, reported Jenscare.

As summarized in the company’s press release, the study enrolled 114 patients from 18 centers in China. Average patient age was approximately 71 years, with an average Society of Thoracic Surgeons score of 7.65. Additionally, 63.2% of patients had a history of hypertension, 41.2% had coronary artery disease, 30.7% had atrial fibrillation, and 91.2% had preoperative New York Heart Association (NYHA) class III/IV.

Jenscare reported that the device success rate at 30 days was approximately 97%, and the average procedure time was approximately 67.53 minutes.

The investigators found that efficacy was demonstrated by 1-year improvement in MR grade, NYHA classification, and quality of life:

• 96.29% of patients demonstrated no above-moderate MR.
• 93.46% of patients showed postoperative NYHA class I/II.
• Patients showed an approximately 20-point increase on average in Kansas City Cardiomyopathy Questionnaire score.
• 6-minute walk distance increased by approximately 82 meters from baseline.

The safety indicators included all-cause mortality of 1.8%, incidence of unplanned mitral valve intervention/surgery of 5.3%, and incidence of stroke of 1.8%. Additionally, the incidence of renal failure, myocardial infarction, major bleeding, device releasing/locking failure, and clip-related hemolysis were all 0.9%. No significant events were seen in single-leaflet device attachment or device-related air embolism, stated Jenscare.